Mithridion reports encouraging results from Phase I Alzheimer’s trial
Mithridion, a biopharmaceutical company, has announced encouraging results from a Phase I pharmacokinetic and clinical study of MCD-386, its lead drug candidate for Alzheimer’s disease. The Phase I
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.